EMD Serono company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

emdserono.com

Founded Year

1981

About EMD Serono

EMD Serono is the biopharmaceutical business. The company develops and offers therapies for specialty-care conditions, like multiple sclerosis, infertility and cancer.

EMD Serono Headquarter Location

One Technology Place

Rockland, Massachusetts, 02370,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing EMD Serono

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

EMD Serono is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

EMD Serono Patents

EMD Serono has filed 13 patents.

The 3 most popular patent topics include:

  • Plasma physics
  • Radio electronics
  • Radio frequency antenna types
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/1/2018

10/22/2019

Military radio systems, Radio electronics, Audio equipment manufacturers, Radio technology, Vacuum tubes

Grant

Application Date

3/1/2018

Grant Date

10/22/2019

Title

Related Topics

Military radio systems, Radio electronics, Audio equipment manufacturers, Radio technology, Vacuum tubes

Status

Grant

Latest EMD Serono News

Opzelura cream well-tolerated, effective for treating atopic dermatitis

May 10, 2022

Disclosures: Bissonnette reports serving as an advisory board member, consultant, speaker or investigator and receiving honoraria or grants from AbbVie, Arcutis, Arena Pharma, Aristea, Asana BioSciences, BELLUS Health, Bluefin Biomedicine, Boehringer Ingelheim, CARA, Dermavant, Eli Lilly, EMD Serono, Evidera, Galderma, GlaxoSmithKline, Incyte, Inmagene Bio, Kiniksa, Kyowa Kirin, LEO Pharma, Novan, Pfizer, Ralexar, RAPT Therapeutics, Regeneron, Respivant, Sanofi-Genzyme, Sienna, Target RWE and Vyne Therapeutics; and being an employee and shareholder of Innovaderm Research. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Data published in the American Journal of Clinical Dermatology showed that Opzelura cream was a well-tolerated and effective topical treatment for patients with atopic dermatitis. Opzelura (ruxolitinib, Incyte) — a potent, selective inhibitor of Janus kinase (JAK) 1 and JAK2 — is a topical formulation developed to maximize its clinical effect on skin and minimize the likelihood of absorption, according to the study researchers. To evaluate the safety profile and efficacy of ruxolitinib, Robert Bissonnette, MD, FRCPC, CEO and medical director at Innovaderm, and colleagues enrolled 41 patients in a maximum-use trial. Two patients discontinued due to reasons deemed unrelated to treatment. The median affected body surface area at baseline was 31.2% and the mean EASI was 20.8. Enrolled patients continuously applied 1.5% ruxolitinib cream twice daily for 28 days on all atopic dermatitis lesions. At follow-up, 31.7% of patients experienced treatment-emergent adverse events, most of which were mild or moderate in severity. The researchers determined that six of these adverse events may have been possibly related to treatment among four patients. The mean maximal plasma concentration of ruxolitinib peaked at 4 hours after first application. The concentrations were relatively flat over the 28-day dosing period and were lower than the peak on day 1. Overall, plasma concentrations of ruxolitinib showed no significant change in the systemic circulation and were related to the amount of cream applied and the percentage of body surface area treated. At 28 days, 35.9% of patients achieved IGA treatment success. Among the 37 patients who continued treatment to day 56, 56.8% achieved IGA treatment success. Most patients had clear or almost clear skin by day 28 with further improvements at day 56. “Ruxolitinib cream was generally well tolerated, with most [adverse events] of mild or moderate severity,” Bissonnette and colleagues wrote. “Transient increases in mean platelet count at day 15 were observed, which were within the normal range and spontaneously returned to baseline levels by day 28. The underlying mechanism is not clear; however, the increased platelet counts did not appear to have clinical implications.” Read more about

EMD Serono Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

EMD Serono Rank

  • When was EMD Serono founded?

    EMD Serono was founded in 1981.

  • Where is EMD Serono's headquarters?

    EMD Serono's headquarters is located at One Technology Place, Rockland.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.